Volume 5, Issue 3, September 2020, Page: 24-30
Parkinson’s Disease Treatment Using Cell Transplantation
Sana Khalid, University of Sargodha, Sargodha, Pakistan
Received: Apr. 22, 2020;       Accepted: May 14, 2020;       Published: Oct. 27, 2020
DOI: 10.11648/j.rs.20200503.12      View  139      Downloads  43
Abstract
The testing of human fetus mesencephalic tissue with intrastriatal transplantation clinically that are rich in dopamine producing neurons. Parkinson’s disease patient showed cell transplantation works and in many cases produces impervious improvements. Due to the poor availability of tissues, this method could only be administered in fewer number of patients, and acclimatization was very difficult, leads to immense deflection in operative outcomes. For transplantation, undifferentiasted (stem) cells and special (reprogrammed) cells could be availed potentially to emolument dopamine producing neurons.From human embryonic stem cells dopamine producing neurons that will be of the appropriate substantia nigra phenotype can be emolumented in larger numbers and soon will be ready for application in patients. Dopamine producing neurons obtained from pluripotent stem cells of human are supposed to be used for clinical transplantation. In a controlled clinical studies, the present data justifies leading in away with these dopamine producing neurons, that should be tested by choosing desirable patients, anticipation of cells and methods of transplantation.
Keywords
Human Fetus Mesencephalic Tissue, Dopamine Producing Neurons, Human Pluripotent Stem Cells, Stem Cells Transplantation, Human Embryonic Stem Cells, Reinnervation, Denervated Striatum
To cite this article
Sana Khalid, Parkinson’s Disease Treatment Using Cell Transplantation, Rehabilitation Science. Vol. 5, No. 3, 2020, pp. 24-30. doi: 10.11648/j.rs.20200503.12
Copyright
Copyright © 2020 Authors retain the copyright of this article.
This article is an open access article distributed under the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Reference
[1]
Brkund A, Stenevi U. 1979 Reconstrucyon of the nigrostriatal dopamine pathway by intraceberal nigral transplants. Brain Res 177, 55-560.
[2]
Perlow MJ, Freed WJ, Hoffer BJ, Seiger A, Olson L, Wyatt RJ. 1979 Brain grafts reduce motor abnormalities produced by dstruction of nigrostriatal dopamine system. Science 204, 643-647.
[3]
Backlund EO, Granberg PO, Hamberger B, Knutsson E, Martensson A, Swdvall G, Geiger A, Olson L 1985 transplantation of adrenal medullary tissue to striatum in parkinsonism. First clinical trials. J. Neurosurg. 62, 169-173.
[4]
Lindvall O, Backlund EO, Frade L, Sedvall G, Freedman R, Hoffer B, Nobin a, seiger a, olson l.1987 Transplantation in parkinson’s disease: two major cases of adrenal medullary grafts to the putamen. Ann. neurol. 22, 457-468.
[5]
Lindvall o.2013 developing dopaminergic cell therapy for parkinson’s disease-give up or move forward? Mov. Disord. 28, 268-273.
[6]
(2015) Press Release International Stem Cell Corporation Receives Authorization to Initiate Phase I/IIa Clinical Trial of ISC-hpNSC for the Treatment of Parkinson’s Disease: http://www.internationalstemcell.com/profiles/investor/ResLibraryView.asp?ResLibraryID=80072&GoTopage=1&Category=958&BzID=1468&G=583
[7]
(2015) Press release, International Stem Cell Corporati- on. http://www.internationalstemcell.com/profiles/investor/NewsPrint.asp?b=1468&ID=80129&m=rl&pop=1&Nav=0&g=583&t=1983.
[8]
Brundin P, Strecker R. E., Clarke D. J., Widner H., Nilsson O. G., Astedt B, Lindvall O., & Bjorklund A (1988) Can human fetal dopamine neuron grafts provide a therapy for Parkin- son’s disease? Prog Brain Res, 78, 441-448.
[9]
Brundin P, Barker RA, & Parmar M (2010) Neural graft- ing in Parkinson’s disease Problems and possibilities. Prog Brain Res, 184, 265-294. [5] Thompson L, & Bjorklund A (2012) Survival, differentia- tion, and connectivity of ventral mesencephalic dopamine neurons following transplantation. Prog Brain Res, 200, 61-95.
[10]
Barker RA, Drouin-Ouellet J, & Parmar M (2015) Cell- based therapies for Parkinson disease-past insights and future potential. Nat Rev Neurol, 11, 492-503.
[11]
Freed CR, Greene PE, Breeze RE, Tsai WY, DuMouchel W, KaoR, Dillon S., Winfield H., Culver S., Trojanowski J. Q., Eidelberg D., & FahnS (2001) Transplantation of embryonic dopamine neurons for severe Parkinson’s disease. N Engl J Med, 344, 710-719.
[12]
Olanow CW, Goetz CG, Kordower JH, Stoessl AJ, Sossi V, Brin MF, Shannon KM, Nauert GM, Perl DP, Godbold J, & Freeman TB (2003) A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson’s disease. Ann Neurol, 54, 403-414.
Browse journals by subject